knowledge -WSS

knowledge

author：entertainment 2025-09-29 01:07:06 - browse：75467

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Venture capitalist Bob Kocher on the state of digital health

focus

entertainment

WSS

How doctors and nurses shape Google's AI

A revolution in caring for preterm infants

Arc Institute generative AI designs new CRISPR systems

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Criminal prosecution for violating HIPAA: an emerging threat

Medicare to cover more brain scans related to Alzheimer’s drugs

leisure time

knowledge

hotspot

Psychedelics group wrestles with new pharma identity

Second House panel advances two

Trump demands the U.S. pay no more for drugs than other countries … again

There’s no way to know how good AI health technologies are

United colonoscopy coverage change 'may cost lives,' doctors say

Addiction experts warn against a second 'war on drugs'

Medical leaders decry Supreme Court decision on affirmative action

NVIDIA and Google execs on the future of AI and drug discovery

Dobbs anniversary: the lost opportunity of abortion as health care

How doctors and nurses shape Google's AI

focus

Big Tobacco's 'harm reduction': Is it for real, or a sham?

What the Wegovy shortage looks like for doctors — and for patients

What the Wegovy shortage looks like for doctors — and for patients

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Military medical care influenced by rank and race, new study finds

Cytokinetics CEO stresses company can launch heart drug on its own

focus

entertainment

knowledge

leisure time